A generic semaglutide injection to promote weight loss is now approved in Canada, Health Canada says.
The regulator said the product submission, called Svemia, was filed by Canadian-based Apotex and is a generic version of the brand name drug Wegovy, sold by Denmark’s Novo Nordisk
Monday’s announcement by Health Canada marks its third such generic semaglutide product approval.
Health Canada said Svemia is approved for use once a week to treat people age 12 and older for chronic weight management in combination with a reduced-calorie diet and increased physical activity
The first two generic semaglutide injections were to treat Type 2 diabetes in adults.
GLP-1s and cancer prevention: What’s known and what isn’t
Generic versions of Novo Nordisk’s Ozempic from India-based Dr. Reddy’s Laboratories and Apotex were approved earlier this year.
Health Canada noted it’s reviewing six other submissions for generic semaglutide from different companies.
